# US 2003/0203897 A1 · 2,4-Disubstituted thiazolyl derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203897 A1
- Document ID: US20030203897A1
- Status: Published application
- Kind: A1
- Application number: 10/220,350
- Filed: 2002-08-29
- Published: 2003-10-30
- Earliest claimed: 2000-03-01
- Inventors: Christopher Love; Jean Pierre Frans Van Wauwe; Marc De Brabander; Ludwig Cooymans; Nele Vandermaesen; Ludo Edmond Josephine Kennis
- Web page: https://patentgrep.com/patent/US20030203897A1

## CPC

- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 277/42: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention concerns the use of a compound of formula (I′) 1 a N-oxide, pharmaceutically acceptable addition salt, quaternary amine and stereochemically isomeric form thereof, wherein Q is optionally substituted C3-6cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl; or Q is a radical of formula 2 wherein X and Y each independently are O, NR3, CH2 or S, with R3 being hydrogen or C1-4alkyl; q is 1 to 4; Z is O or NR4 with R4 being hydrogen or C1-4alkyl; r is 1 to 3; L is optionally substituted phenyl or L is Het with Het being an optionally substituted five- or six-membered heterocyclic ring or an optionally substituted bicyclic heterocyclic ring; for the manufacture of a medicament for the prevention or the treatment of diseases mediated through cytokines.

## Claims

### Claim 1

Use of a compound for the manufacture of a medicament for the prevention or the treatment of diseases mediated through cytokines, wherein the compound is a compound of formula
87
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof,
wherein
Q is C3-6cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, each of said rings optionally being substituted with up to three substituents each independently selected from halo; hydroxy; cyano; carboxy; azido; amino; mono- or di(C1-6alkyl)amrino; C1-6alkyl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, amino, mono-or di(C1-4alkyl)amino; C1-6alkyloxy; C1-6alkylthio; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; arylC1-6alkyloxy; aryloxy; polyhaloC1-6alkyl; polyhalo-C1-6alkyloxy; polyhalo-C1-6alkylcarbonyl; C1-4alkyl-S(═O)n— or R1HN—S(═O)n—; or
Q is a radical of formula
88
wherein X and Y each independently are O, NR3, CH2 or S, with R3 being
hydrogen or C1-4alkyl;
q is an integer with value 1 to 4;
Z is O or NR4 with R4 being hydrogen or C1-4alkyl;
r is an integer with value 1 to 3;
n is an integer with value 1 or 2;
R1 represents hydrogen, or a radical of formula
89
with A being O, S or a bivalent radical of formula —CR2a═N— with CR2a attached to N of formula (a-1); and
R2a being hydrogen, C1-6alkyl or C1-6alkyloxy;
L is phenyl, optionally substituted with up to 4 substituents each independently being selected from halo, hydroxy, amino, cyano, carboxyl, mono-or di(C1-4alkyl)amino, C1-6alkyl, C1-6alkyl substituted with hydroxy or C1-4alkyloxy or amino or mono-or di(C1-4alkyl)amino, polyhaloC1-6alkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy, aminocarbonyl, mono-or di(C1-6alkyl)aminocarbonyl, C1-6alkyl-C(═O)—NH—, C1-6alkyloxy-C(═O)—NH—, H2N—C(═O)—NH— or mono- or di(C1-4alkyl)amino-C(═O)—NH—; or
L is Het;
Het is (i) an optionally substituted five- or six-membered heterocyclic ring containing at least two double bonds and containing 1, 2, 3 or 4 heteroatoms each independently being selected where possible from N, S or O;
(ii) an optionally substituted five- or six-membered heterocyclic ring containing at least two double bonds and containing 1, 2, 3 or 4 heteroatoms each independently being selected where possible from N, S or O and being fused through 2 carbon atoms, 2 nitrogen atoms or 1 carbon and 1 nitrogen atom with another optionally substituted five- or six-membered ring, which contains, apart from the atoms in common with the first ring, only carbon atoms; the latter ring may be unsaturated, partially unsaturated or saturated;
(iii) an optionally substituted five- or six-membered heterocyclic ring containing at least two double bonds and at least one heteroatom and being fused through 2 carbon atoms, 2 nitrogen atoms or 1 carbon and 1 nitrogen atom with another optionally substituted five- or six-membered heterocyclic ring, which contains, apart from the atoms in common with the first ring, at least one heteroatom; the latter ring may be unsaturated, partially unsaturated or saturated; said bicyclic ring system contains in total from 2 up to 6 heteroatoms, each independently being selected where possible from N, S or O;
wherein Het being a monocyclic ring system may optionally be substituted with up to 4 substituents, and wherein Het being a bicyclic ring system may optionally be substituted with up to 6 substituents, said substituents each independently being selected from halo, hydroxy, amino, cyano, carboxyl, mono-or di(C1-4alkyl)amino, C1-6alkyl, C1-6alkyl substituted with hydroxy or C1-4alkyloxy or amino or mono-or di(C1-4alkyl)amino, polyhaloC1-6alkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy, aminocarbonyl, mono-or di(C1-6alkyl)aminocarbonyl, C1-6alkyl-C(═O)—NH—, C1-6alkyloxy-C(═O)—NH—, H2N—C(═O)—NH— or mono- or di(C1-4alkyl)amino-C(═O)—NH—;
aryl is phenyl, optionally substituted with up to five substituents each independently selected from halo, hydroxy, C1-6alkyl, polyhaloC1-6alkyl, CIl6alkyloxy, C1-6alkylthio, cyano, nitro, amino, mono-or di(C1-6alkyl)amino.

### Claim 2 (depends on 1)

Use of a compound as claimed in claim 1 wherein L is phenyl, optionally substituted with up to 4 substituents each independently being selected from halo, hydroxy, amino, mono or di(C1-4alkyl)amino, C1-6alkyl, polyhaloC1-6alkyl or C1-6alkyloxy; or L is Het, optionally substituted with up to 4 substituents when Het is a monocyclic ring, or up to 6 substituents when Het is a bicyclic ring, said substituents each independently being selected from halo, hydroxy, amino, mono or di(C1-4alkyl)amino, CIl6alkyl, polyhaloC1-6alkyl or C1-6alkyloxy; and wherein aryl is phenyl, optionally substituted with up to five substituents each independently selected from halo, hydroxy, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, cyano, nitro, amino, mono-or di(C1-6alkyl)amino; and wherein Q is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, each of said rings optionally being substituted with up to three substituents each independently selected from halo; hydroxy; cyano; carboxy; azido; amino; mono- or di(C1-6alkyl)amino; CI,6alkyl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, amino, mono-or di(C1-4alkyl)amino; C1-6alkyloxy; C1-6alkylthio; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; arylC1-6alkyloxy; aryloxy; polyhaloC1-6alkyl; polyhalo-C1-6alkyloxy; polyhaloC1-6alkylcarbonyl; C1-4alkyl-S(═O)n— or R1HN—S(═O)n—; or
Q is a radical of formula
90
wherein X and Y each independently are O, NR3, CH2 or S, with R3 being
hydrogen or C1-4alkyl;
q is an integer with value 1 to 4;
Z is O or NR4 with R4 being hydrogen or C1-4alkyl;
r is an integer with value 1 to 3;

### Claim 3 (depends on 1, 2)

Use of a compound as claimed in claim 1 or 2 provided that L is other than optionally substituted phenyl and provided that when L is Het then Het is other than optionally substituted isothiazolyl, 2-pyridyl, benzthiazolyl, benzoxazinyl and benzoxazinonyl.

### Claim 4 (depends on 1, 2, 3)

Use of a compound as defined in any one of claims 1 to 3 for the manufacture of a medicament for the prevention or the treatment of diseases mediated through activation of the adenosine A3 receptor.

### Claim 5 (depends on 1, 2, 3)

Use according to any one of claims 1 to 3 wherein the diseases mediated through cytokines are TNF-α (Tumor Necrosis Factor-alpha) and IL-12 (Interleukin 12) mediated diseases.

### Claim 6 (depends on 1, 2, 3, 5)

Use according to any one of claims 1, 2, 3 and 5 wherein the diseases are inflammatory or autoimmune diseases.

### Claim 7 (depends on 6)

Use according to claim 6 wherein the inflammatory or autoimmune diseases are rheumatoid arthritis, Crohn's disease, irritable bowel disease or colitis.

### Claim 8

A compound of formula
91
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof,
wherein
Q is C3-6cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, each of said rings optionally being substituted with up to three substituents each independently selected from halo; hydroxy; cyano; carboxy; azido; amino; mono- or di(C1-6alkyl)amino; C1-6alkyl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, amino, mono-or di(C1-4alkyl)amino; C1-6alkyloxy; C1-6alkylthio; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; arylC1-6-alkyloxy; aryloxy; polyhaloC1-6alkyl; polyhalo-C1-6alkyloxy; polyhalo-C1-6alkylcarbonyl; C1-4alkyl-S(═O)n— or R1HN—S(═O)n—; or
Q is a radical of formula
92
wherein X and Y each independently are O, NR3, CH2 or S, with R3 being
hydrogen or C1-4alkyl;
q is an integer with value 1 to 4;
Z is O or NR4 with R4 being hydrogen or C1-4alkyl;
r is an integer with value 1 to 3;
n is an integer with value 1 or 2;
R1 represents hydrogen, or a radical of formula
93
with A being O, S or a bivalent radical of formula —CR2a═N— with CR2a attached to N of formula (a-1); and
R2a being hydrogen, C1-6alkyl or C1-6alkyloxy;
L is 3-halophenyl, optionally substituted with 1, 2 or 3 substituents each independently being selected from halo, hydroxy, amino, cyano, carboxyl, mono-or di(C1-4alkyl)amino, C1-6alkyl, C1-6alkyl substituted with hydroxy or C1-4alkyloxy or amino or mono-or di(C1-4alkyl)amino, polyhaloC1-6alkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy, aminocarbonyl, mono-or di(C1-6alkyl)aminocarbonyl, C1-6alkyl-C(═O)—NH—, C1-6alkyloxy-C(═O)—NH—, H2N—C(═O)—NH— or mono- or di(C1-4alkyl)amino-C(═O)—NH—; or
L is Het;
Het is (i) an optionally substituted five- or six-membered heterocyclic ring containing at least two double bonds and containing 1, 2, 3 or 4 heteroatoms each independently being selected where possible from N, S or O;
(ii) an optionally substituted five- or six-membered heterocyclic ring containing 3) at least two double bonds and containing 1, 2, 3 or 4 heteroatoms each independently being selected where possible from N, S or O and being fused through 2 carbon atoms, 2 nitrogen atoms or 1 carbon and 1 nitrogen atom with another optionally substituted five- or six-membered ring, which contains, apart from the atoms in common with the first ring, only carbon atoms; the latter ring may be unsaturated, partially unsaturated or saturated;
(iii) an optionally substituted five- or six-membered heterocyclic ring containing at least two double bonds and at least one heteroatom and being fused through 2 carbon atoms, 2 nitrogen atoms or 1 carbon and 1 nitrogen atom with another optionally substituted five- or six-membered heterocyclic ring, which contains, apart from the atoms in common with the first ring, at least one heteroatom; the latter ring may be unsaturated, partially unsaturated or saturated; said bicyclic ring system contains in total from 2 up to 6 heteroatoms, each independently being selected where possible from N, S or O;
wherein Het being a monocyclic ring system may optionally be substituted with up to 4 substituents, and wherein Het being a bicyclic ring system may optionally be substituted with up to 6 substituents, said substituents each independently being selected from halo, hydroxy, amino, cyano, carboxyl, mono-or di(C1-4alkyl)amino, C1-6alkyl, C1-6alkyl substituted with hydroxy or C1-4alkyloxy or amino or mono-or di(C1-4alkyl)amino, polyhaloC1-6alkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy, aminocarbonyl, mono-or di(C1-6alkyl)aminocarbonyl, C1-6alkyl-C(═O)—NH—, C1-6alkyloxy-C(═O)—NH—, H2N—C(═O)—NH— or mono- or di(C1-4alkyl)amino-C(═O)—NH—;
aryl is phenyl, optionally substituted with up to five substituents each independently selected from halo, hydroxy, C1-6alkyl, polyhaloC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, cyano, nitro, amino, mono-or di(C1-6alkyl)amino.
provided that
Het is other than optionally substituted isothiazolyl, 2-pyridyl, benzthiazolyl, benzoxazinyl and benzoxazinonyl;
when Q is phenyl substituted with hydroxy or C1-6alkyloxy and carboxy or C1-6alkyloxycarbonyl then Het is other than 3-pyridyl or 4-pyridyl;
when Q is phenyl then Het is other than 2-thienyl, 2-furanyl, 5-bromo-2-benzofuranyl, 1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl, 2-benzofuranyl, 5-chloro-2-benzimidazolyl, 2-benzimidazolyl, 3-pyridyl, 4-pyridyl, 6-methyl-thiazolo [3,2-b] [1,2,4]triazol-5-yl, 2,6-dimethyl-thiazolo [3,2-b] [1,2,4]triazol-5-yl or 5,6-dihydro-4,5-dimethyl-2(H)-3-pyranonyl;
when Q is 2-methyl-phenyl then Het is other than 2-thienyl, 2-benzofuranyl or 3-pyridyl;
when Q is 4-methoxy-phenyl then Het is other than 2-furanyl, 2-pyrazinyl, 3-pyridyl, 4-pyridyl, 1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl, 1,2-dihydro-6-ethyl-2-oxo-3-cyano-5-pyridyl, 4-(dimethylamino)-1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl, 1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-cyano-5-pyridyl or 3-amino-6-methyl-2(11H)-5-pyridinonyl;
when Q is 2-methoxy-phenyl then Het is other than 2-pyrazinyl, 5-chloro-2-benzimidazolyl, or 3-pyridyl;
when Q is 4-chloro-phenyl then Het is other than 2-furanyl, 2-thienyl, 5-chloro-2-benzimidazolyl, 2-pyrazinyl, 3-pyridyl!, 4-pyridyl or 5,6-dihydro-4,5-dimethyl-2(H)-3-pyranonyl;
when Q is 3-chloro-phenyl then Het is other than 2-thienyl, 3-pyridyl or 1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl;
when Q is 2-chloro-phenyl then Het is other than 2-thienyl;
when Q is 3-methyl-phenyl then Het is other than 2-thienyl or 3-pyridyl;
when Q is 2,3-dichloro-phenyl then Het is other than 3-pyridyl;
when Q is 2-ethoxy-phenyl or 3-methoxy-phenyl then Het is other than 2-pyrazinyl;
when Q is 4-bromo-phenyl then Het is other than 2-thienyl, or 5-chloro-2-benzimidazolyl;
when Q is 4-fluoro-phenyl then Het is other than 4-pyridyl;
when Q is 1-naphthyl then Het is other than 2-thienyl, or 3-pyridyl;
when Q is 4-methyl-phenyl then Het is other than 2-furanyl, 2-thienyl, 3-pyridyl, 2-pyrazinyl or 5,6-dihydro4,5-dimethyl-2(H)-3-pyranonyl;
when Q is 4-ethoxy-phenyl then Het is other than 2-pyrazinyl;
when Q is 2-naphthyl, 2-carboxy-phenyl, 3-carboxy-phenyl, 4-carboxy-phenyl, 4-amino-phenyl or 3-chloro-2,6-dinitro-4-trifluoromethyl-phenyl then Het is other than 2-thienyl;
when Q is 4-benzenesulfonamide then Het is other than 2-furanyl, or 1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl;
when Q is N-methyl4-benzenesulfonamide then Het is other than 3-thienyl;
when Q is N-butyl-4-benzenesulfonamide then Het is other than 2-furanyl;
when Q is 2-pyridyl then Het is other than 2-pyrazinyl;
when Q is 3-pyridyl then Het is other than 2-thienyl, 3-pyridyl, 4-pyridyl or 1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl;
when Q is 2,4-dichloro-phenyl then Het is other than 2-pyrazinyl, or 4-pyridyl; when Q is 4-pyridyl then Het is other than 3-quinolinyl or 1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl;
when Q is 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl, 4-hydroxyphenyl, 4-methylthiophenyl, or 4-methylsulfinylphenyl then Het is other than 1,2-dihydro-6-methyl-2-oxo-3-cyano-5-pyridyl.

### Claim 9 (depends on 8)

A compound as claimed in claim 8 wherein L is Het and Het, being a monocyclic ring system, may optionally be substituted with up to 4 substituents, and Het, being a bicyclic ring system, may optionally be substituted with up to 6 substituents, said substituents each independently being selected from halo, hydroxy, amino, mono or di(C1-4alkyl)amino, C1-6alkyl, polyhaloC1-6alkyl or C1-6alkyloxy; and wherein Q is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, each of said rings optionally being substituted with up to three substituents each independently selected from halo; hydroxy; cyano; carboxy; amino; mono- or di(C1-6alkyl)amino; C1-6alkyl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, amino, mono-or di(C1-4alkyl)amino; C1-6alkyloxy; C1-6alkylthio; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; arylC1-6alkyloxy; aryloxy; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylcarbonyl; C1-4alkyl-S(═O)n— or R1HN—S(═O) n; or Q is a radical of formula
94
wherein X and Y each independently are O, NR3, CH2 or S, with R3 being
hydrogen or C1-4alkyl;
q is an integer with value 1 to 4;
Z is O or NR4 with R4 being hydrogen or C1-4alkyl;
r is an integer with value 1 to 3;

### Claim 10 (depends on 8)

A compound as claimed in claim 8 wherein L is imidazolyl, imidazothiazolyl, pyrimidinyl, thienyl, thiazolyl, furanyl, 3-pyridyl, 4-pyridyl, pyrazolyl, indolyl, indazolyl, quinolinyl, benzofuranyl, pyrrolopyridyl, imidazopyridyl, imidazopyrazinyl, imidazopyrimidinyl, imidazopyridazinyl, pyrazolopyridyl, with each heterocycle optionally substituted with one, two, three or four substituents selected from halo, amino, C1-6alkyl, polyhaloC1-6alkyl, aminocarbonyl or C1-6alkyl-C(═O)—NH—.

### Claim 11 (depends on 8, 9, 10)

A compound as claimed in any one of claims 8 to 10 wherein L is indolyl, 3-imidazo[1,2-a]pyridyl, 3-imidazo[1,5-a]pyridyl, 3-pyridyl, quinolinyl, imidazopyrimidinyl, imidazopyrazinyl, imidazothiazolyl, 5-pyrimidinyl, furanyl, thiazolyl, imidazolyl, pyrrolopyridyl, pyrazolopyridyl.

### Claim 12 (depends on 8, 9, 10, 11)

A compound as claimed in any one of claims 8 to 11 wherein L is 3-imidazo[1,2-a]pyridyl, 3-imidazo[1,5-a]pyridyl, imidazothiazolyl, 3-pyridyl or pyrrolopyridyl.

### Claim 13 (depends on 8)

A compound as claimed in claim 8 wherein L is 3-fluorophenyl or 3,5-difluorophenyl.

### Claim 14 (depends on 8, 10, 11, 12, 13)

A compound as claimed in any one of claims 8, 10, 11, 12 or 13 wherein Q is 3-pyridyl, 4-pyridyl, naphthalenyl, C3-6cycloalkyl, phenyl, 1,3-benzodioxolyl, 2,3-dihydro-benzofuranyl, 2,3-dihydro-1,4-benzodioxinyl, benzthiazolyl, indazolyl, benzimidazolyl or imidazopyridyl.

### Claim 15 (depends on 8, 10, 11, 12, 13, 14)

A compound as claimed in any one of claims 8, 10, 11, 12, 13 or 14 wherein Q is phenyl, 3-pyridyl, 4-pyridyl, benzthiazolyl or imidazopyridyl, each of said rings being optionally substituted with up to three substituents selected from halo, cyano, C1-6alkyl, C1-6alkyloxy or polyhaloC1-6alkyl.

### Claim 16 (depends on 8)

A compound as claimed in claim 8 wherein the compound is selected from
2-thiazolamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[3-(trifluoromethyl)phenyl];
2-thiazolamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[4-(trifluoromethyl)phenyl];
2-thiazolamine, 4-(3-pyridinyl)-N-[3-(trifluoromethyl)phenyl];
2-thiazolamine, N-(3-chlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl;
2-thiazolamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(3-methylphenyl);
2-thiazolamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[3-(methylthio)phenyl];
2-thiazolamine, N-(4-chlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl;
2-thiazolamine, N-(3-bromophenyl)-4-imidazo[1,2-a]pyridin-3-yl;
2-thiazolamine, N-(2,3-dichlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl;
2-thiazolamine, N-(2,3-dichlorophenyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl);
2-thiazolamine, N-(4-bromophenyl)-4-imidazo[1,2-a]pyridin-3-yl;
2-thiazolamine, N-(2,3-dichlorophenyl)-4-imidazo[1,5-a]pyridin-3-yl;
2-thiazolamine, 4-imidazo[2,1-b]thiazol-5-yl-N-[3-(trifluoromethyl)phenyl];
2-thiazolamine, N-(2,3-dichlorophenyl)-4-imidazo[2,1-b]thiazol-5-yl;
2-thiazolamine, 4-(3-pyridinyl)-N-(3-methyl-4-fluorophenyl);
2-thiazolamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(3-methyl-4-fluorophenyl);
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and stereochemically isomeric form thereof.

### Claim 17 (depends on 8, 13)

A compound as claimed in claim 8 or 13 wherein the compound is selected from
2-thiazolamine, 4-(3-fluorophenyl)-N-phenyl;
2-thiazolamine, 4-(3-fluorophenyl)-N-[4-methoxyphenyl];
2-thiazolamine, 4-(3-fluorophenyl)-N-[4-(trifluoromethyl)phenyl]; and
2-thiazolamine, 4-(3-fluorophenyl)-N-[3-pyridyl];
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.

### Claim 18 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A compound as claimed in any one of claims 8 to 17 for use as a medicine.

### Claim 19 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 8 to 17.

### Claim 20 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19)

A process of preparing a composition as claimed in claim 19 characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one of claims 8 to 17.

### Claim 21 (depends on 1, 8)

A process of preparing a compound as claimed in claim 8 characterized by
a) reacting an intermediate of formula (II) or formula (III) or reacting an intermediate of formula (II) and (III) with an intermediate of formula (IV)
95
with L and Q defined as in claim 8 and W1 being a suitable leaving group, in a suitable reaction-inert solvent,
b) reacting an intermediate of formula (II-a) with an intermediate of formula (IV)
96
with Q defined as in claim 8, H2N-L1 being defined as L according to claim 1 provided that L is substituted with NH2, and W1 being a suitable leaving group, in a suitable reaction-inert solvent and in the presence of a suitable acid;
c) reducing an intermediate of formula (I-b-interm.)
97
with L defined as in claim 8, Q1-NH2 being defined as Q according to claim 8 provided that Q is substituted with NH2, in a suitable solvent and in the presence of a suitable reducing agent;
and, if desired, converting compounds of formula (I) into each other following art known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms, quaternary amines or N-oxide forms thereof.

### Claim 22 (depends on 8)

A product containing (a) a compound as defined in claim 8, and (b) another anti-inflammatory or immunosuppressive compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of inflammatory or autoimmune diseases.

### Claim 23 (depends on 8)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 8, and (b) another anti-inflammatory or immunosuppressive compound.
